Today's FDA

New England Journal of Medicine

Volumn 352, Issue 3, 2005, Pages

  Slater, Eve E ^a,b,c  

^a Dept of Health and Human Services ^*

^b VERTEX PHARMACEUTICALS   (United States)

^c AnorMED   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEVICE; DRUG COST; DRUG INFORMATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; FOOD INDUSTRY; FOOD SAFETY; HUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

COST CONTROL; DRUG APPROVAL; DRUG COSTS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 19944428402     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsb042278     Document Type: Review

References (54)

1. McClellan MB. The Food and Drug Administration's strategic action plan: protecting and advancing America's health: responding to new challenges and opportunities. August 2003. (Accessed December 30, 2004, at http://www.fda.gov/ oc/mcclellan/strategic.html.)
2. FY 2004 Justification of Estimates for Appropriations Committees. Promoting public health through patient, food, and consumer safety. Rockville, Md.: Food and Drug Administration, 2003. (Accessed December 30, 2004, at http://www.fda.gov/oc/oms/ofm/budget/2004/bib1.htm.)
3. Taylor H. CDC, NIH, FAA, FDA get highest ratings of eleven federal government agencies. Harris Poll no. 73. (Accessed December 30, 2004, at http://www.harrisinteractive.com/harris_poll/index.asp?PID=422.)
4. Sinclair U. The jungle. New York: Doubleday, Page, 1906:102.
5. Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 21 U.S.C. 379, 106 Stat. 4491 (Oct. 29, 1992).
6. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 21 U.S.C. 355a, 111 Stat. 2296 (Nov. 21, 1997).
7. Public Health Security and Bioterrorism Preparedness and Response Act of 2002, Pub. L. No. 107-188 (June 12, 2002).
8. PDUFA III: five-year plan. Rockville, Md.: Food and Drug Administration, July 2003. (Accessed December 30, 2004, at http://www.fda.gov/oc/pdufa3/ 2003plan/default.htm.)
9. Office of Planning. PDUFA III commitments: new goals and approaches. Rockville, Md.: Food and Drug Administration, 2003. (Accessed December 30, 2004, at http://www.fda.gov/oc/pdufa/report2002/2002-PDUFAIIICommitments.html.)
10. Department of Health and Human Services. Washington, D.C.; Office of Management and Budget, 2004. (Accessed December 30, 2004, at http://www.whitehouse.gov/omb/budget/fy2005/print/hhs.html.)
11. FDA's budget proposal for FY 2004. Rockville, Md.: Food and Drug Administration, 2003. (Accessed December 30, 2004, at http://www.fda.gov/bbs/ topic/ANSWERS/2003/ANS01195.html.)
12. Department of Agriculture. Washington, D.C.: Office of Management and Budget, 2004. (Accessed December 30, 2004, at http://www.whitehouse.gov/omb/ budget/fy2005/agriculture.html.)
13. Hilts PJ. Protecting America's health: the FDA, business, and one hundred years of regulation. New York: Alfred A. Knopf, 2003:xv.
14. McClellan MB. Remarks of the Commissioner of Food and Drugs. Food Drug Law J 2003;58:191-204.
15. Prior notice of imported food under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Washington, D.C.: General Accounting Office, October 23, 2003. (GAO-04-194R.) (Accessed December 30, 2004, at http://www.gao.gov/decisions/majrule/d0419r.pdf.)
16. Approval times for priority and standard NMEs: calendar years 1993-2003. Rockville, Md.: Food and Drug Administration, 2004. (Accessed December 30, 2004, at http://www.fda.gov/cder/rdmt/NMEapps93-03.htm.)
17. The pink sheet: FDA clears 21 NMEs in 2003; average approval time is 16.6 months. Pink Sheet 2004;66:1-3.
18. Drug companies will de-emphasize blockbuster development strategies, according to the Tufts CSDD. Boston: Tufts Center for the Study of Drug Development, January 6, 2003. (Accessed December 30, 2004, at http://155.212.10.127/NewsEvents/RecentNews.asp?newsid=24.)
19. FDA's fast track initiative cut total drug development time by three years, according to Tufts CSDD. Boston: Tufts Center for the Study of Drug Development, November 13, 2003. (Accessed December 30, 2004, at http://155.212.10.127/NewsEvents/RecentNews.asp?newsid=34.)
20. Office of Planning. Report on PDUFA goals: original new product applications. Rockville, Md.: Food and Drug Administration, 2003. (Accessed December 30, 2004, at http://www.fda.gov/oc/pdufa/report2002/2002-onpa.html.)
21. Temple R. Policy developments in regulatory approval. Stat Med 2002;21:2939-48.
22. McAuslane N, Anderson C, Walker S. The changing regulatory environment: reality and perception. R&D briefing no. 42. Surrey, England: Centre for Medicines Research, August 2004.
23. Total cost to develop a new prescription drug, including cost of post-approval research, is $897 million. Boston: Tufts Center for the Study of Drug Development, May 13, 2003. (Accessed December 30, 2004, at http://155.212.10.127/NewsEvents/RecentNews.asp?newsid=29.)
24. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
25. Food and Drug Administration. Effect of user fees on drug approval times, withdrawals, and other agency activities. September 17, 2002. Washington, D.C.: General Accountability Office, 2002. (GAO-02-958.) (Accessed December 30, 2004, at http://www.gao.gov/docdblite/summary.php?recflag=&accno= A05090&rptno=GAO-02-958.)
26. Major management challenges and program risks. Washington, D.C.: General Accountability Office, January 2003:46-75. (GAO-03-101.)
27. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safely of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999;281:1728-34.
28. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988;260:967-70.
29. Benson JO, McGhee K, Coplan P, et al. Fat redistribution on indinavir-treated patients with HIV infection: a review of postmarketing cases. J Acquir Immune Defic Syndr 2000;25:130-9.
30. Merck announces voluntary worldwide withdrawal of Vioxx. Whitehouse Station, N.J.: Merck, 2004. (Accessed December 30, 2004, at http://www.merck. com/newsroom/press_releases/product/2004_0930.html.)
31. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001;357:1870-5.
32. Guidance for industry: postmarketing safely reporting for human drug and biological products including vaccines: draft guidance. Rockville, Md.: Food and Drug Administration, March 2001.
33. Managing the risks from medical product use: creating a risk management framework. Rockville, Md.: Food and Drug Administration, May 1999.
34. Trontell A. Expecting the unexpected - drug safely, pharmacovigilance, and the prepared mind. N Engl J Med 2004;351:1385-7.
35. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999;53:177-90.
36. Bennett DA, Jull A. FDA: untapped source of unpublished trials. Lancet 2003;361:1402-3.
37. Bone HG. Presented at the 37th Annual Meeting of the Drug Information Association, Denver, July 8-12, 2001. abstract.
38. FDA rule requires bar codes on drugs and blood to help reduce errors. 2004. (Accessed December 30, 2004, at http://www.fda.gov/oc/initiatives/barcode- sadr/.)
39. Angell M. Shattuck Lecture - evaluating the health risks of breast implants: the interplay of medical science, the law, and public opinion. N Engl J Med 1996;334:1513-8.
40. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002;287:2273-5.
41. Prescription drugs. FDA oversight of direct-to-consumer advertising has limitations. Washington, D.C.: General Accounting Office, October 28, 2002. (GAO-03-177.) (Accessed December 30, 2004, at http://www.gao.gov/new.items/ d03177.pdf.)
42. Wilde Mathews A, Martinez B. Celebrex drama may finally prompt changes at the FDA. Wall Street Journal. December 20, 2004:B1.
43. Zuger A. Rx: Canadian drugs. N Engl J Med 2003;349:2188-90.
44. Rising drug spending is spurring switches of prescription drugs to OTC status in U.S. and Europe, according to CSDD. Boston: Tufts Center for the Study of Drug Development, September 3, 2003. (Accessed December 30, 2004, at http://155.212.10.127/NewsEvents/RecentNews.asp?newsid=32.)
45. McClellan MB. Protecting and advancing America's health through 21st century patient safety: speech before the Urban Institute. November 2003. (Accessed December 30, 2004, at http://www.fda.gov/oc/speeches/2003/ urbaninstitute1112.html.)
46. Advanced technologies to lower health care costs and improve quality. Westborough: Massachusetts Technology Collaborative, 2003.
47. Halvorson GC, Isham GJ. Epidemic of care: a call for safer, better, and more accountable health care. San Francisco: Jossey-Bass, 2003.
48. Walter LC, Davidowitz NP, Heineken PA, Covinsky KE. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure. JAMA 2004;291:2466-70.
49. Rawlins MD. NICE work - providing guidance to the British National Health Service. N Engl J Med 2004;351:1383-5.
50. Abraham J. The pharmaceutical industry as a political player. Lancet 2002;360:1498-502.
51. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet 2001;357:1544-5.
52. Galson S, Kweder S, Houn F, Raczowski V, Honig PK. The FDA and the Lancet: an exchange. Lancet 2001;358:415.
53. Department of Health and Human Services. Financial relationships and interests in research involving human subjects: guidance for human subject protection. Fed Regist 2004;69(92):26393-7.
54. Henderson JA, Smith JJ. Financial conflict of interest in medical research: overview and analysis of institutional controls. Food Drug Law J 2003;58:251-68.